GovernAtlasSubmit your product ↗
Discover platforms/Suki AI, Inc.

GOVERNATLAS / PRODUCT DOSSIER

Suki

Suki describes ambient clinical documentation and medical transcription software for healthcare teams. Its platform terms describe a BAA for patient information; performance and the terms of an individual deployment require separate evaluation.

Explore the product ↗Add to comparison ↗

01 / CONTEXT & SCOPE

Understand the proposition.
Define the boundary.

The decision to make

Evaluate the boundary between transcription, draft documentation and the clinician's approved record. A vendor's integration description does not show what your particular EHR configuration writes, who can change it or what happens when the connection fails.

What this record does not establish

The posted platform terms describe a business-associate relationship and a BAA. They do not establish that an agreement has been executed for the buyer, that every integration is covered or that the generated documentation is clinically safe. Confirm the agreement and service boundary for the proposed deployment.

1 current source · 2 published assertions
Source coverage is a research boundary, not a quality score.

02 / YOUR EVALUATION

Turn interest into a useful trial.

Open the evaluation playbook ↗
A

A test worth running

Run a synthetic consultation with an interrupted recording, a correction and a negated symptom. Ask the vendor to show the draft, review step and transfer into a test record. Interrupt the integration and inspect how an incomplete or duplicate entry is handled. Do not use real patient information for this demonstration.

GovernAtlas editorial proposal. We have not performed this test.

B

Evidence to bring back

  1. Reconcile the scenario with the approved test note and retain every correction.
  2. Obtain the applicable order form and BAA with a named service and integration boundary.
  3. Assign owners for failed transfers, access reviews, retention and incident escalation.

03 / DOCUMENTED EVIDENCE

Read the claim. Inspect the basis.

Each statement retains its classification and preserved source. A vendor assertion is not an independent test result.

01
vendor asserted

Suki's platform terms identify Suki as a business associate and say the parties will execute a BAA permitting transmission of specified patient PHI in connection with platform use. Scope: the posted HIPAA contractual provision; an executed BAA, the customer's order form and third-party integration coverage have not been verified.

Source, dates & preserved provenanceSuki AI, Inc. — Posted platform terms and HIPAA provisions ↗

Authority: vendor owned
Observed 2026-08-27 · Reviewed 2026-11-02 · current until 2026-12-02

Artifact SHA-256: 0a8e365c17f2c750b08b086cb082196e10521820fe79954eaa6dd04eaa68dd22

The hash identifies the preserved capture. The live source may have changed.

02
vendor asserted

Suki's terms describe its platform as SaaS using machine learning, conversational AI and process automation for medical transcription. Scope: healthcare documentation functions described by the vendor, not an independently tested clinical result.

Source, dates & preserved provenanceSuki AI, Inc. — Posted platform terms and HIPAA provisions ↗

Authority: vendor owned
Observed 2026-08-27 · Reviewed 2026-11-02 · current until 2026-12-02

Artifact SHA-256: 0a8e365c17f2c750b08b086cb082196e10521820fe79954eaa6dd04eaa68dd22

The hash identifies the preserved capture. The live source may have changed.

Source register

Brand asset provenance

Organization identity asset from its official website; inclusion does not imply endorsement.

Official website ↗ · Original asset ↗

04 / BEFORE YOU COMMIT

Better questions.
A clearer decision.

Resolve these with the provider and your own evaluation team.

01

Which service, plan, region and integrations does the proposed BAA cover?

02

What retention, deletion and model-training terms apply to our exact workflow?

03

Who validates outputs and owns the clinical or operational decision?

Regulatory applicability requires a separate, current determination. Inclusion is not certification.

COMPLIANCE / CLAIMS, SCOPE & GAPS

Start with the requirement.
Inspect the support.

Prepare your vendor review ↗

These labels describe this dossier’s current evidence coverage. A published mention may be a framework mapping, a qualified assertion or a limitation; it is not a compliance finding.

HIPAA

Published mention available

US healthcare privacy & security

Vendor documents BAA availability

The platform terms say the parties will execute a BAA for PHI use. Obtain the applicable signed agreement and confirm which services and integrations it covers.

Read the source-attributed statement

Suki's platform terms identify Suki as a business associate and say the parties will execute a BAA permitting transmission of specified patient PHI in connection with platform use. Scope: the posted HIPAA contractual provision; an executed BAA, the customer's order form and third-party integration coverage have not been verified.

vendor asserted

Suki AI, Inc. — Posted platform terms and HIPAA provisions ↗

Explore HIPAA evidence ↗

For HIPAA-regulated use, request service-specific BAA eligibility, processing scope and responsibility details. Missing evidence here does not establish noncompliance. Payment cannot alter these evidence labels.

KEEP THE RECORD USEFUL

A dossier should stand up to scrutiny.

Have a source that changes this picture? Submit it for editorial review.

Raise an evidence issue ↗